. home.aspx



Enterprise Therapeutics nabs Novartis VC exec as new CMO

February 10, 2020 / FierceBiotech

Britain-based biotech Enterprise Therapeutics has hired Novartis Venture Fund managing director David Morris, M.D., as its next chief medical officer. Morris, who will continue to serve as the fund’s operating partner, will lead Enterprise’s development strategy and drive its two lead respiratory programs through the clinic. These are ETD002, a first-in-class TMEM16A potentiator, and ETD001, an ENaC blocker, both of which are hoping to help cystic fibrosis (CF) patients.